Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

ate the safety and tolerability of treatment with Amigal. The secondary objective was to evaluate certain pharmacodynamic measures of treatment, including effects on a-GAL (the target enzyme deficient in Fabry patients) and levels of GL-3 (the substrate that builds up in the cells of patients) in cells and tissues affected by the disease. An additional objective was the preliminary assessment of cardiac and renal function.

The four open-label, multi-national Phase 2 trials of Amigal enrolled 18 men and 9 women with Fabry disease between the ages of 17 and 65. The four studies examined various dose levels and frequencies of Amigal administration and had 12 or 24 week primary treatment arms with an optional treatment extension.

Twenty-six patients completed the primary treatment arms and all entered the optional treatment extension. The 26 patients had 21 different missense genetic mutations that cause Fabry disease. The mutations represented the full spectrum of Fabry patients, including those with both early-onset and late- onset forms of the disease. Twenty-three patients are currently being treated with Amigal under the treatment extension, including 8 who have been treated for more than a year and 4 who have been treated for almost 2 years.

"The positive results of these first trials of a pharmacological chaperone in Fabry disease are impressive," said Raphael Schiffmann, M.D., Lead Investigator at the Metabolic Neurology Branch of the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health, and a principal investigator in one of the Amigal clinical trials. "I believe this technology has the potential to be an important new treatment option for many Fabry disease patients."

The key findings in the Phase 2 studies were:

* Amigal was generally safe and well-tolerated at all doses evaluated. No

drug-related serious adverse events were reported during the primary


'/>"/>
SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
(Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... , July 10, 2014 Research and ... of the "International Photonic Integrated Circuit (Monolithic ... to 2019" report to their offering. ... The concept of photonic integration traces its roots ... The promise of photonic integration went unexplored and ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... Scott Karasinski, PharmD to Run Medical Services Department of ... Expanding Independent Medical Education Agency, ... the appointment of Scott Karasinski, PharmD to the,position of ... as Director in the Medical Affairs and Drug Information,department ...
... Inc., the leading,systems biology tools company, announced today ... and have added additional capability. This,will provide GSK ... access to MetaCore, MapEditor and MetaBase. MetaCore is,GeneGo,s ... data,featuring a comprehensive collection of pathway maps and ...
... at BIO CEO & Investor Conference, LOUISVILLE, Colo., Feb. ... it will host a conference call on,Tuesday, February 26, 2008 ... earnings. Additionally, Replidyne will present at an upcoming,investor conference in ... follows:, Kenneth J. Collins, President and CEO, ...
Cached Biology Technology:L&M Healthcare Communications, LLC, Hires Scott Karasinski, PharmD 2GSK Extends GeneGo License and Adds New Products 2Replidyne to Report 2007 Fourth Quarter and Year-End Earnings 2Replidyne to Report 2007 Fourth Quarter and Year-End Earnings 3
(Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... exists that cannabinoid receptor type 1 can ... influx, and reduce neurotransmitter release. However, some ... can increase extracellular Ca2+ influx and increase ... team, Tongji Hospital Affiliated to Tongji Medical ... China used whole cell voltage-clamp and calcium ...
(Date:7/10/2014)... Albuquerque, and other major cities in New Mexico, nearly ... municipal wastewater rather than precious potable water supplies. Across ... of all golf courses receive treated effluent. Reusing the ... Additionally, golf courses and homeowners alike fertilize their lawns ... is nitrate. A New Mexico State University turfgrass expert ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2'Tailored' water -- the latest in lawn care 2
... a person's under stress or injured, the adrenal gland ... normal. But the hormone's effects are many and varied, ... memories with short-term exposure, while impairing learning if there's ... its effects,understanding how cortisol is made is essential to ...
... has emerged as a promising alternative for ... and tissues, circumventing the complications associated with ... or regenerate damaged tissue by using engineered ... regeneration and eventually integrate into the host ...
... and rheumatoid arthritis occur when the immune system fails ... where the molecular breakdowns responsible for such failures occur. ... and the Dana-Farber Cancer Institute have identified a key ... autoimmune disease, findings that may help scientists develop new ...
Cached Biology News:Scientists unravel clue in cortisol production 2Cracking open the black box of autoimmune disease 2
Request Info...
supplied with 10x reaction buffer...
... yeast/leuconostoc overproducer ATP: D-hexose 6- ... One unit of HK will ... in 1 min at 25C ... of G6P-DH will oxidize 1 ...
Request Info...
Biology Products: